Skip to main content

Market Overview

Hoth Therapeutics Stock Rallies As Lead Peptide Candidate Shows Encouraging Preclinical Antiviral Activity Against COVID-19

  • Hoth Therapeutics Inc (NASDAQ: HOTH) soars after reporting new in vitro data for its lead peptide candidate for HT-002 to treat COVID-19.
  • Data showed that HT-002 inhibited 50% of the cytopathic effect (CPE) of the SARS-CoV-2 virus at 61.7 µM (the EC50). No cytotoxicity was demonstrated at concentrations of up to 200 µM of the peptide.
  • Hoth plans to pursue further preclinical animal studies to support the lead peptide's therapeutic potential and investigate the route of administration.
  • Price Action: HOTH shares are trading higher by 55% at $3.42 in premarket trading on the last check Tuesday.

Related Articles (HOTH)

View Comments and Join the Discussion!

Posted-In: Covid-19Biotech News Penny Stocks Health Care FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at